Progress in chemoprevention drug development: The promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer - A plan to move forward

Gary J. Kelloff, Scott M. Lippman, Andrew J. Dannenberg, Caroline C. Sigman, Homer L. Pearce, Brian J. Reid, Eva Szabo, V. Craig Jordan, Margaret R. Spitz, Gordon Mills, Vali A. Papadimitrakopoulou, Reuben Lotan, Bharat B. Aggarwal, Robert S. Bresalier, Jeri Kim, Banu Arun, Karen H. Lu, Melanie E. Thomas, Helen E. Rhodes, Molly A. BrewerMichele Follen, Dong M. Shin, Howard L. Parnes, Jill M. Siegfried, Alison A. Evans, William J. Blot, Wong Ho Chow, Patricia L. Blount, Carlo C. Maley, Kenneth K. Wang, Stephen Lam, J. Jack Lee, Steven M. Dubinett, Paul F. Engstrom, Frank L. Meyskens, Joyce O'Shaughnessy, Ernest T. Hawk, Bernard Levin, William G. Nelson, Waun Ki Hong

Research output: Contribution to journalReview article

228 Citations (Scopus)

Abstract

This article reviews progress in chemopreventive drug development, especially data and concepts that are new since the 2002 AACR report on treatment and prevention of intraepithelial neoplasia. Molecular biomarker expressions involved in mechanisms of carcinogenesis and genetic progression models of intraepithelial neoplasia are discussed and analyzed for how they can inform mechanism-based, molecularly targeted drug development as well as risk stratification, cohort selection, and end-point selection for clinical trials. We outline the concept of augmenting the risk, mechanistic, and disease data from histopathologic intraepithelial neoplasia assessments with molecular biomarker data. Updates of work in 10 clinical target organ sites include new data on molecular progression, significant completed trials, new agents of interest, and promising directions for future clinical studies. This overview concludes with strategies for accelerating chemopreventive drug development, such as integrating the best science into chemopreventive strategies and regulatory policy, providing incentives for industry to accelerate preventive drugs, fostering multisector cooperation in sharing clinical samples and data, and creating public-private partnerships to foster new regulatory policies and public education.

Original languageEnglish (US)
Pages (from-to)3661-3697
Number of pages37
JournalClinical Cancer Research
Volume12
Issue number12
DOIs
StatePublished - Jun 15 2006
Externally publishedYes

Fingerprint

Chemoprevention
Biomarkers
Pharmaceutical Preparations
Neoplasms
Public-Private Sector Partnerships
Foster Home Care
Genetic Models
Public Policy
Motivation
Industry
Carcinogenesis
Clinical Trials
Education
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Progress in chemoprevention drug development : The promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer - A plan to move forward. / Kelloff, Gary J.; Lippman, Scott M.; Dannenberg, Andrew J.; Sigman, Caroline C.; Pearce, Homer L.; Reid, Brian J.; Szabo, Eva; Jordan, V. Craig; Spitz, Margaret R.; Mills, Gordon; Papadimitrakopoulou, Vali A.; Lotan, Reuben; Aggarwal, Bharat B.; Bresalier, Robert S.; Kim, Jeri; Arun, Banu; Lu, Karen H.; Thomas, Melanie E.; Rhodes, Helen E.; Brewer, Molly A.; Follen, Michele; Shin, Dong M.; Parnes, Howard L.; Siegfried, Jill M.; Evans, Alison A.; Blot, William J.; Chow, Wong Ho; Blount, Patricia L.; Maley, Carlo C.; Wang, Kenneth K.; Lam, Stephen; Lee, J. Jack; Dubinett, Steven M.; Engstrom, Paul F.; Meyskens, Frank L.; O'Shaughnessy, Joyce; Hawk, Ernest T.; Levin, Bernard; Nelson, William G.; Hong, Waun Ki.

In: Clinical Cancer Research, Vol. 12, No. 12, 15.06.2006, p. 3661-3697.

Research output: Contribution to journalReview article

Kelloff, GJ, Lippman, SM, Dannenberg, AJ, Sigman, CC, Pearce, HL, Reid, BJ, Szabo, E, Jordan, VC, Spitz, MR, Mills, G, Papadimitrakopoulou, VA, Lotan, R, Aggarwal, BB, Bresalier, RS, Kim, J, Arun, B, Lu, KH, Thomas, ME, Rhodes, HE, Brewer, MA, Follen, M, Shin, DM, Parnes, HL, Siegfried, JM, Evans, AA, Blot, WJ, Chow, WH, Blount, PL, Maley, CC, Wang, KK, Lam, S, Lee, JJ, Dubinett, SM, Engstrom, PF, Meyskens, FL, O'Shaughnessy, J, Hawk, ET, Levin, B, Nelson, WG & Hong, WK 2006, 'Progress in chemoprevention drug development: The promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer - A plan to move forward', Clinical Cancer Research, vol. 12, no. 12, pp. 3661-3697. https://doi.org/10.1158/1078-0432.CCR-06-1104
Kelloff, Gary J. ; Lippman, Scott M. ; Dannenberg, Andrew J. ; Sigman, Caroline C. ; Pearce, Homer L. ; Reid, Brian J. ; Szabo, Eva ; Jordan, V. Craig ; Spitz, Margaret R. ; Mills, Gordon ; Papadimitrakopoulou, Vali A. ; Lotan, Reuben ; Aggarwal, Bharat B. ; Bresalier, Robert S. ; Kim, Jeri ; Arun, Banu ; Lu, Karen H. ; Thomas, Melanie E. ; Rhodes, Helen E. ; Brewer, Molly A. ; Follen, Michele ; Shin, Dong M. ; Parnes, Howard L. ; Siegfried, Jill M. ; Evans, Alison A. ; Blot, William J. ; Chow, Wong Ho ; Blount, Patricia L. ; Maley, Carlo C. ; Wang, Kenneth K. ; Lam, Stephen ; Lee, J. Jack ; Dubinett, Steven M. ; Engstrom, Paul F. ; Meyskens, Frank L. ; O'Shaughnessy, Joyce ; Hawk, Ernest T. ; Levin, Bernard ; Nelson, William G. ; Hong, Waun Ki. / Progress in chemoprevention drug development : The promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer - A plan to move forward. In: Clinical Cancer Research. 2006 ; Vol. 12, No. 12. pp. 3661-3697.
@article{88edd9d4d3044e8383e46c40cec25a26,
title = "Progress in chemoprevention drug development: The promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer - A plan to move forward",
abstract = "This article reviews progress in chemopreventive drug development, especially data and concepts that are new since the 2002 AACR report on treatment and prevention of intraepithelial neoplasia. Molecular biomarker expressions involved in mechanisms of carcinogenesis and genetic progression models of intraepithelial neoplasia are discussed and analyzed for how they can inform mechanism-based, molecularly targeted drug development as well as risk stratification, cohort selection, and end-point selection for clinical trials. We outline the concept of augmenting the risk, mechanistic, and disease data from histopathologic intraepithelial neoplasia assessments with molecular biomarker data. Updates of work in 10 clinical target organ sites include new data on molecular progression, significant completed trials, new agents of interest, and promising directions for future clinical studies. This overview concludes with strategies for accelerating chemopreventive drug development, such as integrating the best science into chemopreventive strategies and regulatory policy, providing incentives for industry to accelerate preventive drugs, fostering multisector cooperation in sharing clinical samples and data, and creating public-private partnerships to foster new regulatory policies and public education.",
author = "Kelloff, {Gary J.} and Lippman, {Scott M.} and Dannenberg, {Andrew J.} and Sigman, {Caroline C.} and Pearce, {Homer L.} and Reid, {Brian J.} and Eva Szabo and Jordan, {V. Craig} and Spitz, {Margaret R.} and Gordon Mills and Papadimitrakopoulou, {Vali A.} and Reuben Lotan and Aggarwal, {Bharat B.} and Bresalier, {Robert S.} and Jeri Kim and Banu Arun and Lu, {Karen H.} and Thomas, {Melanie E.} and Rhodes, {Helen E.} and Brewer, {Molly A.} and Michele Follen and Shin, {Dong M.} and Parnes, {Howard L.} and Siegfried, {Jill M.} and Evans, {Alison A.} and Blot, {William J.} and Chow, {Wong Ho} and Blount, {Patricia L.} and Maley, {Carlo C.} and Wang, {Kenneth K.} and Stephen Lam and Lee, {J. Jack} and Dubinett, {Steven M.} and Engstrom, {Paul F.} and Meyskens, {Frank L.} and Joyce O'Shaughnessy and Hawk, {Ernest T.} and Bernard Levin and Nelson, {William G.} and Hong, {Waun Ki}",
year = "2006",
month = "6",
day = "15",
doi = "10.1158/1078-0432.CCR-06-1104",
language = "English (US)",
volume = "12",
pages = "3661--3697",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - Progress in chemoprevention drug development

T2 - The promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer - A plan to move forward

AU - Kelloff, Gary J.

AU - Lippman, Scott M.

AU - Dannenberg, Andrew J.

AU - Sigman, Caroline C.

AU - Pearce, Homer L.

AU - Reid, Brian J.

AU - Szabo, Eva

AU - Jordan, V. Craig

AU - Spitz, Margaret R.

AU - Mills, Gordon

AU - Papadimitrakopoulou, Vali A.

AU - Lotan, Reuben

AU - Aggarwal, Bharat B.

AU - Bresalier, Robert S.

AU - Kim, Jeri

AU - Arun, Banu

AU - Lu, Karen H.

AU - Thomas, Melanie E.

AU - Rhodes, Helen E.

AU - Brewer, Molly A.

AU - Follen, Michele

AU - Shin, Dong M.

AU - Parnes, Howard L.

AU - Siegfried, Jill M.

AU - Evans, Alison A.

AU - Blot, William J.

AU - Chow, Wong Ho

AU - Blount, Patricia L.

AU - Maley, Carlo C.

AU - Wang, Kenneth K.

AU - Lam, Stephen

AU - Lee, J. Jack

AU - Dubinett, Steven M.

AU - Engstrom, Paul F.

AU - Meyskens, Frank L.

AU - O'Shaughnessy, Joyce

AU - Hawk, Ernest T.

AU - Levin, Bernard

AU - Nelson, William G.

AU - Hong, Waun Ki

PY - 2006/6/15

Y1 - 2006/6/15

N2 - This article reviews progress in chemopreventive drug development, especially data and concepts that are new since the 2002 AACR report on treatment and prevention of intraepithelial neoplasia. Molecular biomarker expressions involved in mechanisms of carcinogenesis and genetic progression models of intraepithelial neoplasia are discussed and analyzed for how they can inform mechanism-based, molecularly targeted drug development as well as risk stratification, cohort selection, and end-point selection for clinical trials. We outline the concept of augmenting the risk, mechanistic, and disease data from histopathologic intraepithelial neoplasia assessments with molecular biomarker data. Updates of work in 10 clinical target organ sites include new data on molecular progression, significant completed trials, new agents of interest, and promising directions for future clinical studies. This overview concludes with strategies for accelerating chemopreventive drug development, such as integrating the best science into chemopreventive strategies and regulatory policy, providing incentives for industry to accelerate preventive drugs, fostering multisector cooperation in sharing clinical samples and data, and creating public-private partnerships to foster new regulatory policies and public education.

AB - This article reviews progress in chemopreventive drug development, especially data and concepts that are new since the 2002 AACR report on treatment and prevention of intraepithelial neoplasia. Molecular biomarker expressions involved in mechanisms of carcinogenesis and genetic progression models of intraepithelial neoplasia are discussed and analyzed for how they can inform mechanism-based, molecularly targeted drug development as well as risk stratification, cohort selection, and end-point selection for clinical trials. We outline the concept of augmenting the risk, mechanistic, and disease data from histopathologic intraepithelial neoplasia assessments with molecular biomarker data. Updates of work in 10 clinical target organ sites include new data on molecular progression, significant completed trials, new agents of interest, and promising directions for future clinical studies. This overview concludes with strategies for accelerating chemopreventive drug development, such as integrating the best science into chemopreventive strategies and regulatory policy, providing incentives for industry to accelerate preventive drugs, fostering multisector cooperation in sharing clinical samples and data, and creating public-private partnerships to foster new regulatory policies and public education.

UR - http://www.scopus.com/inward/record.url?scp=33745683516&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745683516&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-06-1104

DO - 10.1158/1078-0432.CCR-06-1104

M3 - Review article

C2 - 16778094

AN - SCOPUS:33745683516

VL - 12

SP - 3661

EP - 3697

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 12

ER -